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thetical cohort of patients diagnosed with RRMS in the United
States (US). Health states were based on the Kurtzke expanded
disability status scale (EDSS) (higher EDSS scores = increased
disease severity). Relapse and disease progression transition
probabilities for SMA were obtained from natural history
studies. Treatment effects of the immunomodulatory therapies
were estimated by applying a percent reduction to the SMA 
transition probabilities and adjusting for neutralizing antibodies
(NAbs) and treatment discontinuation. Therapy-speciﬁc data
was obtained from clinical trials and long-term follow-up
studies. Transitions among health states occurred in 1-month
cycles for the lifetime of a patient. Costs (2005US$) and out-
comes were discounted at 3% annually. RESULTS: The incre-
mental cost per quality-adjusted life-year (QALY) is $258,465,
$303,008, $395,686, and $310,691 for SCGA, IM-IFNb1-a, 
SC-IFNb1-a and SC-IFNb1-b compared to SMA respectively.
Sensitivity analyses showed results were sensitive to changes in
utilities, disease progression rates, time horizon and
immunomodulatory therapy cost. CONCLUSIONS: Model
results indicated that the immunomodulatory therapies are both
more effective and more costly than SMA in treating RRMS.
Although the reported incremental cost-effectiveness ratios
(ICERs) are well above $50,000/QALY, not all economic evalu-
ations are bounded by this threshold and numerous interventions
with ICERs above this threshold have been deemed valuable by
patients, health care decision-makers and society. This model
suggests that of the immunomodulatory therapies for MS SCGA
is the most cost-effective.
PNL9
COST-EFFECTIVENESS OF TOPIRAMATE FOR MIGRAINE
PREVENTION: A MANAGED CARE PERSPECTIVE
Brown J1, Rupnow M2, Neumann PJ3, Friedman M1, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA, 2Ortho-McNeil
Janssen Scientiﬁc Affairs, LLC,Titusville, NJ, USA, 3Tufts University
School of Medicine, Boston, MA, USA
OBJECTIVES: To estimate the cost-effectiveness of topiramate
(TPM) treatment for migraine prevention versus no preventive
treatment using newly available efﬁcacy and cost data.
METHODS: Model inputs included baseline migraine days per
month (base-case: 7), treatment discontinuation, treatment
response, cost of preventive therapy, cost of acute treatment per
attack (medical and pharmacy services), hours of work lost per
attack, and hourly wage. Model outcomes were expressed
monthly and included the number of migraine days averted, dis-
ability hours, total cost of preventive and acute treatment, and
lost wages. Model inputs were gathered from published litera-
ture, clinical studies of TPM in migraine prevention (double-
blind and open-label extensions), and census data. Unit costs for
resource use were obtained by analyzing actual payments of year
2004 medical claims from a large managed care database.
RESULTS: TPM treatment was associated with a mean reduc-
tion in migraine days of 2.4/month, and 6.5 fewer disability
hours. Acute treatment costs per patient per month (including
pharmacy and medical) were $39 lower ($100 versus $139) and
work loss was $65 lower ($125 versus $190) for TPM preven-
tive arm. The incremental monthly cost per patient of TPM pre-
ventive therapy was $109. Consequently, the total cost in TPM
arm was $5 higher than in no-preventive arm ($109-$39-$65);
incremental total cost per migraine day averted was $2 for TPM
versus no preventive therapy. Results are sensitive to the 
baseline migraine rate: as the rate increases, total cost of 
care decreases, with break-even at 7.4 migraine days/month.
CONCLUSIONS: Economic savings (direct and indirect costs)
associated with lower migraine frequency offset approximately
93% of the cost of preventive therapy, suggesting that TPM is a
cost-effective treatment for migraine prevention.
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OBJECTIVES: A new disease modifying agent for the treatment
of MS, natalizumab (Tysabri), was introduced to the market at
the end of 2004 and withdrawn in early 2005 because of two
cases (one fatal) of progressive multifocal leukoencephalopathy
(PML). In the event that natalizumab is reintroduced to the
market, the present study was conducted to assess the cost-
effectiveness of natalizumab compared to interferon beta-1a
(Avonex) and no treatment. Expected value of perfect informa-
tion (EVPI) and partial EVPI (PEVPI) analyses were conducted
to characterize the existing uncertainty in the model parameters.
METHODS: The main analytical technique used in this study
was incremental cost-effectiveness analysis using a Markov
model. Two-level Monte Carlo simulations were performed to
obtain the EVPI and PEVPI estimates. Health care costs were
derived from the literature. The Disability Status Scale (DSS) was
used as the measure of disability; utility values were assigned to
the 10 DSS disability states based on data from the literature.
Cost valuations were based on the direct health-care costs asso-
ciated with disease relapse and medical care in each disability
state expressed in 2005 US dollars. RESULTS: The Markov
cohort analysis returned the following costs and QALYs: No
Treatment—$175,790 and 30.971 QALYs; interferon beta-1a—
$830,861 and 34.391 QALYs; natalizumab—$1,076,327 and
34.497 QALYs. The incremental cost-effectiveness ratios for
interferon beta-1a and natalizumab compared to no treatment
were: interferon beta-1a—$191,541 per QALY gained; natal-
izumab—$255,399 per QALY gained. CONCLUSIONS: Model
inputs were based on a limited number of available studies and
the results should be interpreted with caution. Nevertheless, the
results of this preliminary analysis suggest that treatment with
interferon beta-1a is somewhat more cost-effective than natal-
izumab. The value of information results indicate that more
information about the transition probabilities and QALY para-
meters are necessary to reduce the uncertainty in the model.
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OBJECTIVES: Payers in Europe and North America have dif-
ferent policies on coverage of multiple sclerosis (MS) disease-
modifying agents (DMAs). With the introduction of Medicare
Part D and in the presence of substantial variation in analytical
methods used to examine cost-effectiveness (CE) of MS DMAs,
an assessment of the models’ features and parameters is neces-
sary to understand and interpret the CE results for clinical prac-
tice and health policy. This study compares the results of CE
models evaluating DMAs (interferon beta-1a, interferon beta-1b,
